drugset / Trial / NCT01918098

Targin for Non-cancer Pain

NCT01918098

Phase 3 Completed 230 enrolled Mundipharma (China) Pharmaceutical Co. Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine the improvement in symptoms of constipation in subjects receiving treatment with oxycodone/naloxone prolonged release tablets (OXN) compared to oxycodone prolonged release tablets (OXY) based on the Bowel Function Index (BFI)

Timeline

Start
2013-09-01
Primary completion
2017-03-30
Completion
2017-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Naloxone Small molecule 2.5 mg
Subject Naloxone Small molecule 5 mg
Subject Naloxone Small molecule 10 mg
Subject Oxycodone Other / unclassified 5 mg
Subject Oxycodone Other / unclassified 10 mg
Subject Oxycodone Other / unclassified 20 mg

Indications

No indication recorded.